Name of the second open as sout -10 WE alines. ('1' Granies approved with approved boulget. GRO-C CUTTER LABORATORIES INC., INTERNATIONAL DIVISION PRELIMINARY 1982 MARKETING PLAN 1 CUTTER LABORATORIES LIMITED. UNITED KINGDOM 1 1

BAYP0000019_073_0001

1982 MARKETING PLAN.

00000000

1

- 1. Overview.
- 2. Objectives.
- 3. Blood Bags.
- 4. Koate.
- 5. Plasbumin.
- 6. Other products.
- 7. Recruitment and Training.
- 8. Supporting Activities.
- 9. Grape Sheets.

10.Summary.

ł

1. OVERVIEW.

Contractor

1981 has proved to be a difficult year for Cutter Laboratories, largely due to factors outside our control, i.e.

- 1.1. Delay in receipt of Cutter Blood Bag licence, received in March. Product hold up in Canada and non-availability of product prevented commencement of trials in Regional Transfusion Centres until June 1981.
- 1.2 Continued delay in obtaining Plasbumin licences.
- 1.3 Koate quality problems, coupled with adverse publicity concerning quality problems with Humanate, the pirate Koate product sold by Speywood Laboratories.
- 1.4 Continuing difficulties in obtaining sufficient Koate in required potencies to support increased sales activities.
- 1.5 Continuing supply problems with Tuta Blood Bags and lack of inventory.

Nevertheless, we feel we have established the Company very firmly in the eyes of both customers and competitors and that we are now well placed to achieve our ambitious plan for 1982.

All of the markets we operate in will continue to be extremely competitive and price will continue to be of major significance.

The major factor which could seriously affect our plans and subsequent performance concerns the proposed introduction of the Travenol I.P.P. "Wedge pack". During 1982 the N.H.S. will undergo re-organisation in that the area level of management will be phased out. The organisation will then consist of about 250 District Management Teams within the existing regions. There will undoubtedly be changes concerning contracting but we do not anticipate any adverse effects on our business activities.

2. OBJECTIVES.

2.1	To achieve or exceed sales	s of 5.ρ17 m dollars.
2.2	To achieve or exceed profi	lt of 198,000 dollars.
2.3	To achieve or exceed sales	by product line as follows:-
	 Tuta blood bags Cutter blood bags Koate. Plasbumin. Other product 	1.386 m dollars. 1.670 m dollars. 1.235 m dollars. 0.637 m dollars.
	5. Other products.	0.089 m dollars

2.4

ş

To hire and train the following personnel :-

- 1. Salesman. Quarter two.
- 2. Salesman. Quarter three.

3. BLOOD BAGS.

٠. .

- 3.1. Objectives.
- 3.2 Codes.

3.3. Market information.

7

- 3.4 Competition.
- 3.5 Stategy.
- 3.6 Periodicities.
- 3.7 Planning assumptions.

l

- 3.1 Objectives.
 - A. Tuta bags.

1. Meet or exceed budget of 1.386 million dollars

2. Increase market share in Scotland from 85% to 90 % +

B. Cutter Bags.

1. Meet or exceed budget of 1.670 million dollars

- C. Sebra.
 - Achieve market penetration at all centres with Sebra products.



ŧ.

۰. ,

BAYP0000019_073_0006

MANY TYPE SHARE

3.2. <u>CODES</u>.

A. Tuta Blood Bags.

States Peterse

	1981 E	stimate	SBE %	1982 B	udget	SBE %
	SBE's '000	Units '000		SBE's <u>'000</u>	Units '000	
Single-	95	95	16	104	104	17
Double	384	192	66	376	188	62
Triple	102	34	17	114	38	19
Misc.	4	4	1	11	11	2
	fan Stringelsen (n. 1997) 1996 - Standard Amerika 1997 - Standard Amerika 1997 - Standard Amerika				1999 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -	
Total	585	325	100	605	341	100
	lan selang akar pang berakan Marina dari pang berakan Marina dari pang berakan Marina dari pang berakan Marina dari pang berakan					
\$'000 <u>Sales</u>		<u>1272</u>			1,386	

ľ

B. Cutter Blood Bags.

ţ

. .

1982 budgeted sales :-

and probability of the

	SBE's <u>'000</u>	SBE %	Units <u>'000</u>	\$ <u>000</u>
Singles	32	5	32	85.0
Doubles	456	70 1	228	1161.0
Triples	162	25	54	424.0
	650 '	100	314	1,670

ANT AVERAGE STREET, ST

3.3. Market Information.

The U.K. market consists of those centres detailed in tables (1) and (2) with estimated 1982 collections. Centres in England and Wales are dominated by Fenwal although during 1981 Biotest have established a foothold in some centres and are currently supplying up 50 % of requirements in some smaller centres.

The Lewisham centre in S.E. London remains 100% Tuta. Centres in Scotland are dominated by Tuta with Fenwal having 15% of the business. Biotest have recently established a small foothold in Scotland at the expense of Fenwal.

The central market issue is the I.P.P. or Travenol " wedge pack" and its proposed introduction in the Autumn of 1981. A number of Regional Transfusion Directors remain firmly opposed to its introduction and we are currently engaged in legal correspondence with the D.H.S.S. concerning the legality of this proposed move. Outside of this issue, centres are moving steadily to a greater use of red cell concentrates and more complete component therapy teaching at hospital level. It is expected that in 1982 most centres in England and Wales will adopt the code-a-bar labelling system.

Table (1)

TOTAL DONATIONS OF BLOOD : ENGLAND AND WALES.

CENTRE	REGION	ESTIMATED NO. OF DONATIONS 1982 ('000)	ESTIMATED CUTTER SALES	8
Newcastle	Northern	145	70 (C)	48
Leeds	Yorkshire	145	70 (C)	48
Sheffield	Trent	165	1976 - Sangara Sanakara, ang sanakara Sang pantang sanakarang sanakarang sa	
Cambridge.	East Anglia.	95	45 (C)	47
Edgware	N.W. Thames.	200	lift-festis	
Brentwood	N.E. Thames.	170		
Lewisham and Canterbury. Tooting.	S.E. Thames.) S.W. Thames.)	300	60 (T)	20
Southampton	Wessex.	95	25 (C)	26
Oxford.	Oxford	1 135	35 (C)	26
Bristol	S. Western	194	45 (C)	23
Birmingham	W. Midlands	220		
Liverpool	Mersey	130	24 (C)	18
Manchester	N. Western	200		
Cardiff	Wales :RTC Card	iff 100		
FOTAL :		2294	374	16
				سینے منتقب

N.B.: C = Cutter Blood Bags.

T = Tuta Blood Bags.

Table (2)

1

÷

S - 443

-16669696-20196-

TOTAL DONATIONS OF BLOOD : SCOTLAND.

CENTRE	REGION	ESTIMATED NO. OF DONATIONS 1982 ('000)	ESTIMATED CUTTER SAL	8 ES —
Glasgow	West.	150	136 (T)	91
Edinburgh	South East.	80	80 (T)	100
Dundee.	East	35	25 (т)	71
Aberdeen	North East.	35	25 (T)	71
Inverness	North	15	15 (T)	100
TOTAL :		315	281	90

7

Table (3)

In the Manual American Street Stree

SUMMARY

TOTAL DONATIONS OF BLOOD

مايايا والمقطعا والمقاوم

England / Wales 2,29	4 374	16
Scotland 319	5 281	90
TOTAL: 2,609	9 655	25

T

3.4 Competition.

ABRICAN

1. Fenwal

Remain the dominant market leader with 85 - 90 % of total U.K. business. They are able to provide a complete service and range of products. Their involvement is so complete that some Regional Transfusion Director's have reacted to this "overkill" and would be happy to use an equivalent alternative system.

2. Biotest.

Launched their bag in the Autumn of 1980 and have established a firm base by merely being available, despite problems at centre and hospital level caused by the necessity to change established systems and procedures.

3. Terumo_.

Rumours persist concerning the introduction of a Terumo product but no concrete evidence is currently available.

4. Others.

Potential home based manufacturers continue to show interest, the most active of which is a Scottish based international Company, C.J. Coates Ltd. This Company have taken over the development commenced by I.C.I., and under their " New Ventures Department " will continue to receive full co-operation from the D.H.S.S. to establish a U.K. manufacturing facility.

3.5. Strategies.

A. Tuta Bags.

Regular servicing of the Scottish market will continue. Because of cost, streamlining of systems and personnel changes, it is expected that Tuta dominance in Scotland will increase during 1982. We will continue to give the necessary support and we expect that our established contacts will enable us to increase our business. The Lewisham sub-centre continues to have severe financial problems and we expect to provide 100% of their 1982 requirements, despite Fenwal efforts to obtain this account. It should be noted that in some centres, particularly Lewisham and Edinburgh, there is currently a move to using more singles and fewer doubles because of system changes.

On a national level we intend to obtain a greater share of the hospital laboratory blood bag market by emphasising the cost and packaging benefits of the Tuta system.

The Scottish market will remain the responsibility of Brian Dyos with support from the Sales Manager and the Northern Sales Representative when required. All representatives will spend time selling the Tuta bag at national hospital level.

B. Cutter Blood Bag.

It is our objective to firmly establish the Cutter bag in the U.K. market during 1982. Account selection and trials are now underway and initial response has been excellent. We intend to provide an all-round service to a number of selected centres. We will be emphasising the unique benefits of the Cutter system including the tamperproof donor needle and administration ports.

The centres chosen to form the basis of our 1982 result are:-

Leeds	Trial in progress.
Cambridge.	Trial in progress.
Newcastle.	Trial commences August 1981.
Bristol, Liverpool.)	Trials to be arranged in
Oxford, Southampton.)	quarter three/four of 1981.

Other centres will be considered as we become more aware of the political situation and any changes which would benefit us.

It is our intention to sell the Sebra system at each centre and at hospital level. The main sales responsibility for the Cutter bag will be Barry Barber's with support from Brian Dyos. The sales representatives, with responsbility at present for Koate, will also be involved where necessary, and will sell the bag at hospital level where appropriate.

3.7 Planning Assumptions.

1.1.2.2.1.2

- Availability of Tuta bags to support sales objectives and enable a good inventory to be built and maintained.
- 2. Introduction of Cutter code-a-bar labelling, to support efforts in centres where this system already exists.
- 3. Cutter bag, CPD-A anticoagulant admended licence, early 1982.
- 4. The availability of Sebra equipment.
- 5. That the Travenol I.P.P. does not become firmly established.

- 4. <u>KOATE.</u>
 - 4.1 Objectives.

4.2 Codes.

4.3 Market information.

4.4 Competition.

4.5 Strategy.

4.6 Periodicty.

ى

4.7 Planning assumptions.

4.1. Objectives.

Sell nine million I.U.'s at a.s.p. of 7p per i.u. (equivalent to 13.72 cents)

4.2 Codes.

650 - 20		6.0 million i.u.
650 - 30		
000 - 30		2.0 million i.u.
650 - 50	para para terdera (d. 1919), para pe Periodo de la compositiva de la composit	1.0 million i.u.

4.3 Market Information.

Total usage of commercial A.H.F. is estimated now (July 81) at 37.5 million i.u.'s within the British Isles. Estimated shares of the commercial companies are as follows:-

4

Armon	17	11	.4 %
111.00		7 1	. 4 5
Immu	.	2.1	.
Tunu	10	21	.3 %
Trave	nol		<u> </u>
ILAV	TOUE	10	.7 %
Cutte			
CULL	=1	13	.2 %
N1-L			
Alpha		\mathbb{Z}	.4 %

See also table (7)

ť.

of the 37.5 million i.u. some 40 % is contracted on a yearly or two-yearly basis by individual Regional Health Authorities. Most authorities contract with at least two companies but some contracts are single-sourced.

During the next two years the National Health Fractionation facilities in England and Wales plan to expand product of A.H.F. concentrate from about 15 million i.u. to 30 million i.u. Their success in achieving this very much depends on proposed changes in Regional Transfusion Centre plasma

collection procedures involving the Travenol " wedge pack " being implemented and on fractionation capacity being expanded. It is felt that while the supply of N.H.S. concentrate will increase, the 30 million i.u. target by 1983 is over-ambitious. It is expected that during the next two years the use of Cryoprecipitate will continue to decrease.

Consequently, while some Regions will receive increased amounts of N.H.S. A.H.F. concentrate and their demand for commercial A.H.F. may fluctuate, that overall, the demand for commercial A.H.F. will show a steady increase.

Total number of centres.117Total number of patients.4500Total number of patients on home treatment1200A.H.F. conc. usage level per H/T patient.25,000 i.u. per annum.

Tables (5) and (6) demonstrate our increasing level of business and number of buying accounts - 1981 over 1980.

						amerana:		
	- E	000	069	- ; 000	80	8100	} ≈	
	TOTAL	1024000	951690	617700	20880	81	26329	Page no. 19
	Dec							
	NON	1		1			1 0	
	Oct	146400					146400	
1	Sept	239680 174560			20880	8100	203540	
	Aug						239680	
	۸ŢIJĹ	284480	4		1		284480	
	June	126880		617700	C		744580	
	May	52000	ſ	I	1	ł	52000	
	<u>April</u>	T	ſ	I		1		
	March	J	951690	00- 1	1	ſ	951690	
	Feb				4			
	Jan			1			1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	
	COUNT.	ford.	boowY€	. Thomas .	ldlesex.	n ton.	 ₹	

BAYP0000019_073_0020

Account	January I.U.	February	March I.U.	April I.U.	May <u>I.U</u>	June <u>I.U</u>	July <u>1.1</u>	Total I.U.	
Oxford.	72,000	50,000	. 239,820	158,400	132,000	247,200	355,630	1,255,100	
Newcastle.	50,000				75,000	150,000	156,000	431,000	
Bristol.	50,000	1	50,000		109,460			209,460	
Edgware.	115,200	1						115,200	
Manchester.			92,400					92,400	
Glasgow				30,250		49,000		79,750	
Cardiff					31,200	1		31,200	-
Liverpool			I		15,600		31,200	46,800	
Huddersfield			•		1	10,400		10,400	an a
Taunton.	7,200						1	7,200	<u>a da angan</u> Nganangan
Leicester.							52,000	52,000	n manan dala Angka tangga ta
Swansea.			•			5,200	1	5,200	
Wessex.						3,120		3,120	
York.							2,600	2,600	•
Plymouth.	2,500							2,500	-
Misc.						8,000		8,000	
	296,900	50,000	382,220	188,650	412,760	423,920	597,430	2,351,930	Page

致於防護

BAYP0000019_073_0021

ge no.28

4.4. Competiton.

Page no. 21

1. Armour

Are the firm market leaders and have a dominant position with Regional contracts. Their strength in some Regions is such that bids offering A.H.F. concentrate at prices under-cutting them by over 1.0 p per i.u. have failed to take the contract away from them. They have recently expressed concern about the falling price level. They defend their contracts strongly and attempt to break those they are not on. At smaller centre level where price is not so important they have a very strong loyalty built up over five years with regular sales activity. Heavy financial support is provided to major users.

2. Immuno.

Have become very aggressive over the last 12 months and have undercut both Armour and Travenol to obtain new A.H.F. business. They have National coverage with about eight sales people selling a broad based product line including P.P.F., Albumin and diagnostic products.

3. Travenol.

Hemofil marketing appears to be controlled from Europe. Their market share has recently fallen. They appear content with a small number of major users who are financially supported and who appear committed to advertising the benefits of Autoplex. To prevent further market share loss they have had to reduce the price of Hemofil.

4. Alpha.

¥ .

Have only one U.K. representative. Prepared to cut price below 6.0 p per i.u. to obtain business. At present this strategy has not produced any business gains. Major supplier to Newcastle and Hospital for Sick Children, London. However this activity will ensure current low price level is maintained for some time.

4.5. Strategy.

Page no. 22

1. Major Accounts.

All major accounts will continue to be subject to intensive sales activity. Funds have been budgeted to allow for support in those centres where it is necessary to obtain a major share of the business.

ŧ

Table (7) shows all regions with details of contracts, present suppliers, price and our 1982 marketing target.

2. Supporting Activities.

Harold Booklets

Harold's secret. Let Harold do it. Harold takes a date.

Poster series.

Series of three.

Series of seven.

Tape/Slide programme.

Heredity and Haemophilia Inside a Bleeding Joint.

World Federation of Haemophilia Booklets.

Echo magazines.

Limited number to key centres.

3. Service Programme.

Exercise programme. Infusion record book . Reconsititution Chart. Home care pack.

4. Meetings.

Support/involvement at :-

- a. Hospital/centre meetings. Staff and patient training.
- b. Haemophilia Society Meetings.
- c. National and International Meetings.
- d. Haemophilia Nurses Association.

Region.	Commercia purchases of AHF		Price	Contract period	1982 Mar- keting obj ective.	
Yorkshire.	. 1.2million	Armour	7.2-7.8	No contract	0.5 millio	n Major account,Leeds our current offer 6.8r
Northern.	4.0 "	Cutter/Alpha	6.75-7.0	n n	2.0 "	Protection - Newcastle.
Wales.	2.0 "	All companies.	6.8 +	n a	1.0 "	Major account - U.H. Wales-developing
Wessex	3.25 "	Travenol/Armour/ Immuno.	7.0	P 11	0.25 "	
S.E. Thames	5.00 "	Travenol/Armour/ Immuno.	7.0	1.8.81- 31.7.81	0.5 "	Only 40% to be contracte
S.W. Thames	0.75 "	Armour	7.0 +	No contract		
Mersey.	1.5 "	Armour/ Immuno.	7.0 +	1.9.80 - 31.8.81	0.5 "	Contract reviewed each year.
Oxford.	4.0 "	Cutter / Armour	7.2 +	1.7.80 - 31.6.82	2.0 "	Protection.
N.E. Thames.	4.2 "	Armour/Immuno.	7.0	1.4.81 - 31.3.82	2.0 "	
Anglia	0.1 "	Armour	7.5	No contract		
S. Western	1.0 "	Cutter/all others.	6.5-7.5	1.8.81 - 31.7.82		
N.W.Thames	0.75 "	Immuno.	6.8	1.7.81 - 30.6.82		
Trent.	1.8 "	Immuno/Travenol Armour/Speywood.	7.2 +	No contract.	0.8 "	
N.Western.		Travenol/Immuno/ Armour.	7.0 +	u u	0.5 "	
W.Midlands	2.5 "	Armour.	7.0	1.8.81 - 31.7.82		
Scotland.	0.75 "	Armour/Cutter.	6.8-7.0	No contract.	0.25	
4isc.	2.2				0.35 "	
	37.5				10.65	neseren serek eren de den er serek i de

BAYP0000019_073_0024

		for year				Page no.24
		Total for	000 ' 6	1,235	lent to	
(Preliminary)		Quarter 4	2 , 700	<u>375</u>	7.0 pence (equivalent	
	<u>Quarterly Sales</u>	Quarter 3	2,400	32 25	lis Mit	
KOATE PERIODICITY (Pr	Quart	Quarter 2	2,250	308	ce per activity je rate of 1.96)	
4.6 KOATE PI		Quarter 1	1,650	325	ited average selling price cents at budget exchange	
			International Units ('000)		Estimated average selling price 13.72 cents at budget exchange	
			Interna ('0	000 ' •	Ш Г 	

5. Pricing.

During quarter 4, 1980 the average market price moved downwards from 8.0p to 7.2 - 7.5p During the first six months of 1981, some of our competitors have quoted below 6 p on contracts and 6.0 p for non contract volume business. Armour have indicated that they are keen to raise the overall price level but with Immuno, Alpha and ourselves keen to increase market share the current lower prices could persist well into 1982. Whatever price changes occur we will defend our recently acquired increase in business with all the tools at our disposal including price where necessary.

4. 19 20 20 20 12

4.7. Planning Assumptions.

1

 A minimum of 6.0 million i.u. Koate in 10ml vials with potency in range 240 - 260 i.u. to be available as per submitted forecast and provided end of year inventory is achieved as planned.

1

2. No major"product reactions"

3. No "pirate " Koate available in U.K.

5. Plasbumin.

- 5.1 Objective.
- 5.2 Codes.
- 5.3 Market information.

- series

- 5.4 Competition.
- 5.5 Strategy.
- 5.6 Planning assumptions.
- 5.7 Periodicity.

¥ .

Ŧ

5.1 Objective.

Sell product - value £ 325,000 (637,000 dollars)

- 5.2 Codes Budgeted Units 5 8 685-20 50 ml 5,800 685-25 250 ml 7,200 685-27 500 ml 1,800 20 % 683-20 50 ml 3,000 683-71 100 ml 1,000 25 % 684-16 20 ml 900 684-20 50 ml 2,400 684-71 100 ml 600
- 5.3 Market Information.
 - 1. Estimated market £ 1.5 1.8 million. (\$3.0 3.7 m)
 - Currently shared by Immuno and Travenol on an estimated 60/40 split.
 - 3. N.H.S. products are distributed via Regional Blood Transfusion centres similar to distribution of F. VIII concentrate produced by N.H.S.
 - 4. Major hospital accounts are supplementing N.H.S. supply by up to 3,000 bottles per year =(to 400 ml of 4.3 % P.P.F.)
 - 5. Major uses are :-
 - 1. Volume replacement/expander.
 - 2. Burns.

- 3. Plasmapheresis Therapeutic, Replacement.
- 4. Renal units.

5.4 Competition.

COMPLETE AND ST

1. Immuno

Currently are very aggressive in pricing. Supply 400 ml 4.3 % P.P.F. to replicate N.H.S. product. Also supply 20 % solution. Have secured a number of major accounts (100 bottles per month)on an annual basis, at prices below £ 1.50 per g. of albumin. At present gaining market share from Travenol.

2. Travenol.

Supply 20 % and 5 % solutions. Have very recently (June81) introduced a 400 ml bottle of 5 % to combat Immuno sales pitch in the P.P.F. market. Have good support in areas where they have traditional all-round support for f. VIII concentrate and blood bags.

3. Kabi

Have licences but are not marketing product.

4. Armour.

ł

Known to be awaiting Albumin product licences. Have well established Hospital and Therapeutics sales force.

5.5. Strategy.

1. Launch

It is our intention to immediately contact all known purchasers of commercial Albumin solutions. We are currently preparing/up-dating our information bank. Prior to launch an action plan will be produced detailing all buying accounts and detailing sales responsibilities.

2. Letter.

All major hospital pharmacy departments will be informed by letter of the availability of Cutter Plasbumin solutions.

3. Pricing.

4

It is our intention to be very competitive to gain business from Travenol and Immuno. Our lowest budget price equates to £ 1.30 (\$ 2.64) per G of Albumin.

5.6. Planning Assumptions.


1

1. Award of licences for 5 % and 25 % by mid- November 1981.

This date has regressed by over 12 months and it is now very important that we have the licences if we are to achieve our ambitious 1982 objective.

ſ

5.7 PLASBUMIN PERIODICITY



ſ.

N.B.: Estimated average selling price is based on £ 1.30 per gram of albumin (Equivalent to \$ 2.54 per gram at budget exchange rate of 1.96)

6. OTHER PRODUCTS.

6.1. General.

6.2 Strategies.

6.3 Competition.

6.4 Action Plans.

6.5 Assistance required from Cutter International.

T

6.6 Periodicity.

1

Disposable Equipment.

6.1 General.

1982 will primarily be a period for an evaluation of both the U.K. disposables market and of the Cutter product range, in order to isolate the products which should be actively promoted. This applies particulaly to the revised product line from Calgary and the items from the new Korean facility. Until the decision is made to hire a salesman whose priority would be disposables, emphasis will be given to those products purchased on an annual tender basis and requiring minimum sales back up.

Hence, Saftiwing is the only product budgeted for in 1982, but introductory sales of Interface, leg bags and transmission sets may also be achieved.

6.2 Strategies.

1. Market entry

Saftiwing is to be launched in quartersthree and four of 1981 to establish the product for 1982.

2. Market.

1

Total market is estimated at 2.5 million units :-

	Nationa	al Hea	alth S	ervice	9		2.	. 25	
Z	Theres		h	1 1					
2	Indeper	Ident	nospi	cals,	otner		0.	. 25	
							ter and the second s		
							- 7	~~	
							2.	.50	

The N.H.S. market consists of 90 Area Health Authorities who buy between 10,000 and 80,000 units on an annual tender basis, plus Scotland which has one central contract.

The independent hospitals, with the exception of the Nuffield Trust hospitals, each have their own buying arrangements.

3. Objectives.

A STATES

Unit sales : 228,000 (representing approx 9.0 per cent of market)

Dollar sales : \$ 89,000

Gross margin : \$ 22,000 (approx 25 per cent margin)

4. Pricing.

Market prices range from 40 cents to 60 cents. The budget is prepared on the assumption that our average selling price will be 40 cents, but higher prices in certain areas are expected.

6.3 Competition.

Abbott is the market leader with up to 80% of the market. A number of other companies with cheaper products account for the remainder.

1

6.4 Action Plans.

t

1. Assumptions.

- i) Market penetration in quarters 3/4 of 1981.
- ii) Successful tenders achieved in 1981, indicating acceptability of product to N.H.S./other customers.

iii) Product must be viewed by potential customers as a reasonable alternative to Abbott's Butterfly, with the price advantage swinging the buyer's preference to Cutter. Compete aggressively for tender business.
 Up to 100 separate contracts are to be tendered for over the year.


l

- 3. Emphasize good stockholding, supply factors.
- 4. Compete for non-contract business at the independent hospitals and other sales outlets.

6.5 Assistance Required from Cutter International.

- 1. Periodic updates on the progress of Saftiwing in other markets.
 - customer objections.

- customer preferences for competitors' products.
- 2. Audio visual material.
- 3. Literature, market studies.



STACKED STATES

Â

7. RECRUITMENT/TRAINING.


7.1 Time Budget.

Type of Account	Number	Calling <u>frequency</u> .	Total calls
Blood Transfusion centres (England & Wales)	15	monthly	180
Major Haemophilia Centres.	30	monthly	360
District Gen.Hospit /Haemophilia centre	als s 250	two monthly	1500
TOTAL CALLS REQUIRE	D :		2040

ť

With 210 selling days per salesman and covering two accounts per day this requires five salesmen.

7.2 Proposed Organisation 1982.



7.3 Recruitment.

Terms and conditions of employment.
 (as per attached 7.3.1)

2. Action plan.
 (attached 7.3.2)

- 4. Profile Selection of sales representatives, (7.3.4)
- 5. Outline product training course. (7.3.5)
- 6. Further training.
 - Albumin training for new/existing salesmen to be incoporated in Training course for new salesmen, January 1982. Assistance will be requested from International for this.
 - Existing sales force is all Xerox P.S.S. trained. New salesmen will attend this course if not attended during last two years.
 - 3. Continued field training
 - Training element to be incorporated in all sales meetings.
 - Specific course to be selected on individual basis in line with individual needs and overall objectives.

t

Salemen

+

y?


Sec. Sec.

							an a	an 1997 - State State (State 2017 - State State 2017 - State State (State State)	Page no.
2	ON DATES	5;/82				6/82 ·	7/82-	. 6/32	
	COMPLETION DATES	1/82				2/82	4/82	2/82	
	RESPONSIBILITY	Barber.	Barber/ Dyos.	Barber.	Dyos.	Barber.	Hollis/Forth	Barber/ Dyos.	
	ACTION	 Interview/select candidates for shortlist. 	 Appoint two salespeople from shortlist. 	3. Check References.	4. Write letters of appointment.	 Write programme. Decide location. Inform guest lecturers. 	 Prepare brief cases. Prepare literature. Prepare records. Organise telephone credit cards Cars. 	1. Select suitable training course.	
	OBJECTIVE	Recruit two salespeople				Provide suitable product Training.	Provide equipment/ literature for sales person.	Prepare sales training programme - if necessary	1

5 214

na an ann an Anna an A Anna an Anna an	
JOB D	ESCRIPTION Page no. 4
JOB TITLE : Salesman	02. LOCATION : Central England
DIVISION :	04. DATE :
JOB HOLDER :	06. REPORTS TO : B.J. Barber.
POSTION IN ORGANIZATION:	Managing Director
countant/Administrator	Sales Manager.
2	Salesman Salesman Salesman
Secretary	Salesman Salesman Salesman
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o	and Blood Bags.
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o	and Blood Bags.
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o	and Blood Bags.
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o sales and marketing policies.	and Blood Bags. ther planned objectives in accordance with
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o sales and marketing policies. <u>FIES</u> : 1. To sell the products within	and Blood Bags. ther planned objectives in accordance with
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o sales and marketing policies. FIES : 1. To sell the products within 2. To meet or exceed quarterly 3. To develop and implement jou	and Blood Bags. ther planned objectives in accordance with the defined territory. sales target. urney and call plans to maximise sales.
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o sales and marketing policies. PIES : 1. To sell the products within 2. To meet or exceed quarterly 3. To develop and implement jou	and Blood Bags. ther planned objectives in accordance with the defined territory. sales target. urney and call plans to maximise sales.
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and o sales and marketing policies. <u>TIES</u> : 1. To sell the products within 2. To meet or exceed quarterly 3. To develop and implement jou 4. To utilise his time in the H amount of direct selling tim 5. To sell the products whenever	and Blood Bags. ther planned objectives in accordance with the defined territory. sales target. urney and call plans to maximise sales. best way possible to achieve the maximum me. er and whenover possible within the a manner to properly illustrate the key
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and of sales and marketing policies. PIES : 1. To sell the products within 2. To meet or exceed quarterly 3. To develop and implement jou 4. To utilise his time in the H amount of direct selling time 5. To sell the products whenever defined territory, in such a features and customer benefit	and Blood Bags. ther planned objectives in accordance with the defined territory. sales target. urney and call plans to maximise sales. best way possible to achieve the maximum me. er and whenover possible within the a manner to properly illustrate the key
MAIN PURPOSE : To sell Cutter Blood Products To achieve sales target and of sales and marketing policies. PIES : 1. To sell the products within 2. To meet or exceed quarterly 3. To develop and implement jou 4. To utilise his time in the H amount of direct selling tim 5. To sell the products whenever defined territory, in such a features and customer benefi 5. To report his activities on provided.	and Blood Bags. ther planned objectives in accordance with the defined territory. sales target. urney and call plans to maximise sales. best way possible to achieve the maximum me. er and whenover possible within the a manner to properly illustrate the key its.

BAYP0000019_073_0042



BAYP0000019_073_0043

	MAN PROFILE FOR SELECTING REPRESEN	NTATIVE	S	Page	no.43
)licants name : ne Address :		Highes [.] Lowest			
.ephone :		POINTS	HPS	LSS	RATIN
First impression .	Likeability & magnestism Good manners and dignity Constructive aggressiveness Personality and appearance	1 2 3 4	10	• 6	
Ac	Under 25 or over 45 From 30 to 45 From 25 to 30	1 2 3	3	2	
Education	Left school early-no further training. Left school early-continued training. Good general education - O levels plus.	1 2 3	3	2	
Health	Looks weak and unfit. Had serious illness - now recovered. Looks in fairly good health Looks extremely fit.	1 2 3 4	4	3	
Family background	Single, Divorced, Widowed or seperated-no dependants. Same as above- but dependants. Happily married-no children Happily married -children	1 2 3 4	4	1	
Sales History.	No sales experience. Some sales experience. At least 2 years sales experience Highly experienced sales person.	1 2 3 4	.ı .ı .4		

		POINTS		LSS	
Financial.	No	TOTATE	про	122	RATIN
	No car, no house, no reserves Car, but no house, or capital.	1			
	House but no car or capital.	2 3			
	House, car and reasonable				
<u>an an Christelle an Christelle an Allen an A</u> Christelle Anna ann an Airtean an Airtean	reserves.	4	4	2	
Speech.	Talks poorly-cannot hold interest	1			
	Talks reasonably well. Talks very clearly and	2			
	convincingly.	3	3	2	
		3	3	, Z	
Loyalty.	Speaks badly of previous				
A	employers.	1			
C.N.	Does not speak badly of previous Employers.				
	Speaks well of previous employers	23	3	2	
Military .	그는 사람이 있는 것 같은 것 같은 것 같은 것 같이 있는 것 같이 있는 것 같은 것 같은 것 같이 없는 것 같이 없다.			4	
experience.	None-& no satisfactory explanation As private/or explanation.	1 2			
	As NCO	3			
	Commissioned officer.	4	4	2	
Ability to sell	Poor - makes no attempt.		<u>en de la s</u> ector de la sector de Este de la sector de		
himself.	Tries - but is very weak.	1 2			
	Quite good & could be trained.	3			
	Excellent in every way.	4	4	3	
Number of jobs	None.			<u>la an an an an</u> Chaol an	
held in last	Over five.	1 2			
10 years.	Three to five.	3			
(Yester and the second s	One to two.	4	4	3	
Motivation	Wants outdoor ish				
	Wants outdoor job meeting people No positive objectives.	$\begin{bmatrix} 1\\2 \end{bmatrix}$			
	Wants to earn more money.	3			
	Wants a career	4	4	3	
Future developm-	\mathbf{x}				
ent possibilities	Poor. 5. Fair	$\begin{bmatrix} 1\\2 \end{bmatrix}$			
energenet et de la posta para Concerna de la posta de la	Good	3			
	Excellent.	4	4	2	
lighest possible	total score.		58		
Lowest suitable t	cotal score.	<u>de la seconda de la seconda</u> Esta de la seconda de la se Esta de la seconda de la sec		34	
.	4	<u> </u>	4		
and total score	ed by this applicant.				

STREET, SALES AND ADDREET, SALES

7.3.5 OUTLINE PRODUCT TRAINING COURSE (ONE WEEKS DURATION)

BERRY COLOR

Blood Components. Plasmapheresis. Blood - Donor to Recipient.

History. Haemophilia. Inheritance. Classification.

U.K. Blood Products Market - Introduction.

FILM : Blood Component Therapy

Koate.

Plasbumin.

Blood Bags.

Other products.

Organisation of the Haemophilia Centre, Selling Koate. Pricing. Contacts, Contracts. Support Programme.

FILM: The Natural Human Resource.

Competition- Review/comparison. Factor VIII Albumin, Blood Bags.

Cascade sequence. Extrinsic/Intrinsic Coagulation. Haemostasis.

Factor VIII Antigen.

Ŧ

Von Willebrands Disease.

Inhibitors Laboratory Assay.

ł

FILM : Fraction v Product .

U.K. Blood Product Market. Current Issues. N.I.B.S.A.C.

Territory Organisation. Reporting.

Administration.

1982 Objectives.

Ŧ

Management of bleeds. Prophylaxis. Home Treatment.

1

1

8. SUPPORTING ACTIVITIES.

 Page no.47

8.1 Sponsorship.

Our planned sales result for 1982 represents a 66 % increase over our estimated 1981 result. We are well aware of the challenge this represents and that in addition to the product group strategies outlined, it will be necessary to provide support for a number of existing and potential major accounts. To this end, \$ 42,000 has been budgeted to be spent on supporting research work, organised via Cutter International, and supporting travel to international meetings and congress.

I.

8.2 Special Promotions.

\$ 10,000 has been budgeted for exclusive Cutter symposium. It is anticipated that these will involve mainly the blood bag area.

8.3 Samples.

\$ 15,000 has been allocated. The major expenditure will be with the Cutter Blood Bag, but some samples of other product groups will be necessary.

8.4 Meetings/Exhibitions.

We intend to attend the following meetings :-I.S.B.T. - Budgeted. A.A.B.B. - Los Angeles

In addition to attending small local exhibitions we will exhibit at the British Society of Haematologists meeting and provide travel assistance for guest speakers at this meeting.

8.5 Advertising/Literature.

No major journal advertising will be undertaken and we will continue to rely with minor exceptions, on literature provided by International.

9. GRAPE SCHEDULES.

•

1

9.1 Total sales and Grape.

· · · · · ·

1

1

4

9.2 Tuta Blood Bags.

ż

9.3 Cutter Blood Bags.

9.4 Koate.

9.5 Plasbumin.

9.6 Thromboscreen.

9.7 Saftiwing.

Unter

9.1 TOTAL SALES & GRAPE* 1980 - 1982

l

WILLED KINGDOM

(\$SN 000)

	186.	8 100			1			Page no.
8 - X +	1982/1981	+ 110 %	+ 1068	+ 127%	•• • • • • • • • • • • • • • • • • • •	+ 627 %	00 ~ +	
sed		100 1	81	허	12	~	1	
Proposed	10	4,993	4,055	8 E ő	502	35,6	1.96	
al		100	83	17	IS	N		
Est. Actual 1981		2,382	1,969	413	362	49	1.93	
S		P 0 P 0 P 0	82	18	61	<u>-</u>	1	
6 Months 1981		685	560	125	134	(6)	1.97	expenses
ъ е Г		8 100	62	21	13	ω		والمالية المراجع والمراجع المتحاط والمتعالي والمتعالي فليتم تستمهم
Budget 1981		4,968	3,939	1,029	644	385	2.12	promotional
lal 30		8 100	79	21	18	m	1	
Actual 1980		1,545	1,220	325	275	50	2.33	(profit) after
		IET SALES	SSO	ROSS PROFIT	ARKETING & Elling Expense	RAPE	XCHANGE RATE	L L L L L L L L L L L L L L L L L L L

MAJOR CUP: BLOOD BAGS



9.2

4

PRODUCT SUB-GROUP TUTA BLOOD BAGS.

TOTAL SALES & GRAPE 1980 - 1982

(\$SN 000)

									3	(\$SN 000)	5\$)		
	Act 19	Actual 1980	Bud 19	Budget 1981	6 Mor 198	Months 1981	Est. Actual 1981	ual	Proposed	osed	8-/+		
				1		T			;	4	61/2867	81	
ET SALES	1,012	F 69	1,272	100	411	100	1,272	100 100	1.369	8 100	ою СО +	80 (
	, ,											do T	
SəL	C # /	/4	942	74	326	79	1,015	80	1,109	81	ଙ ୦ +		
	620												
COSS PROFIT	2	0	0	9 7	85	21	257	20	260	e) I	00 T +		-
DKETTIC -				1									
ILLING EXPENSE	178	18	139	r T	80	50	163	Ę	159	12	- 28		المراجع مرجع المرجع
APE	68	œ	191	I5	S		94	~	101	7	res +		
		l.		T									
CHANGE RATE	2.33	1 •	2.12	ı	1.97	1	1.93	1	1.96	1	8º C: +	1.	
													2

*Gross return (profit) after promotional expenses

;

Page no.50

Ottre

Outer

MAJOR GROUP: BLOOD BAGS

(L1) SLUDI

9.3 PRODUCT SUB-GROUP CUTTER BLOOD BAGS.

l

TOTAL SALES & GRAPE 1980 - 1982

(\$SU 000)

Actual 1980 Budget 1981 6 Months 1981 ET SALES - 1 1 6 1				成づきに話じたりたのなが									
ALES 100 1,767 8 8 100 100		Act 19	ual 180	Bud 196	get 31	6 Mon 198	ths I	Est. Actual 1981	ual	Proposed 1982	sed 12	+/-% 1982/1981	
- - - 1,494 35 - PROFIT - - 273 15 - FING & - - 273 15 - G EXPENSE - - 192 11 - G EXPENSE - - 81 4 - G EXPENSE - 81 4 - - 2.33 - 2.12 - 1.97	r sales	1	8 100	1,767	100	1	100	250	8 100		*		
PROFIT 273 15 - FING 6 NG EXPENSE 192 11 - N - 81 4 - I.97 IGE RATE 2.33 - 2.12 - 1.97	ŝ	1	1	1,494	85	1	1	240	96	1,510	16	WN	ξ I
FING & - 192 11 - VG EXPENSE - - 192 11 - - - - 81 4 - - - 81 4 - IGE RATE 2.33 - 2.12 - 1.97		1	1	273	15	1	1	. 01	4	157	. o	WN	
IGE RATE 2.33 :- 2.12 - 1.97	KETING 6			C 0 -	:								
GE RATE 2.33 - 2.12 - 1.97	TTNG EXPENSE		ı	7.77	-	1	1	69	23	194	R	% 1:51 +	I
- 2.33 - 2.12 - 1.97	Зą	ì	1	81	ব	1	1	(55)	(24)	(37)	(î)	- 37 &	
		2.33	!	2.12	1	1.97		1.93	1	1.96		% + 50	

*Gross return (profit) after promotional expenses

BAYP0000019_073_0052

į

Page no.51

Cutter

MAJOR G. PLASMA FINISHED

9.4 PRODUCT SUB-GROUP KOATE

TOTAL SALES & GRAPE 1980 - 1982

(\$SN 000)

	Act 15	Actual 1980	Budget 1981	get 81	6 Months 1981	ths	Est. Actual 1981	leu	Proposed 1982	osed 32	+/-8 1982/1981		
						T							
ET SALES	524	1 00	1,527	8 100	268	8 100	850	100	1,231	8 100	+ 45 %		
SS	468	89	1,242	81	230	. 98	707	83	751	91	89 9 +		
OSS PROFIT	56	Ţ	285	5 7	38	4	143	17	480	, oi E	+2368	Ī.	
RKETTNG E													
LLING EXPENSE	6 7	6 6	215	7	54	0 2	ŝ	15	141	T	- 8° - 11 +	l I	
APE	(11)	8	02	in	(16)	(9)	18	N	ŝ	28	WN		
		ŀ											
CHANGE RATE	2.33	T	2.12	1	1.97	1	1.93	r	1.56	•	+ 28	1	

*Gross return (profit) after promotional expenses

Page no.52

Ottrer

MAJOR LAP: PLASMA FINISHED

(CI) ATOPT

9.5 PRODUCT SUB-GROUP PLASBUMIN 5 % and 25 %

4

TOTAL SALES & GRAPE 1980 - 1982

(000 USS)

series inter-

Actual 1980 Budget 1981 6 Months 1981 Est. Actual 1981 Proposed 1982 +/-* Fr SALES - 100 369 100 - 100 537 100 - 1982/1981 Fr SALES - 100 369 100 - 100 637 100 - 100 GS - - 240 65 - - - 518 97 - - - 100 GS PROFIT - - 240 65 - - - 518 97 - - - - 100 - - - - - - - - - - - - - - - - - - - 100 - - - - - - - - - - - - - - - - - -		łL								3	(\$SN 000)	s)	
SALES - 100 369 369 100 - 100 637 100 - 100 637 100 -<		Act 19	ual 180	Bud 19	get 81	6 Mon 198	ths I	Est. Act 1981	lau	Propc 198	sed. 12	+/-8	81
- - 240 65 - - - 518 97 - 5 PROFIT - - 129 35 - - 19 3 TTING & - - 129 35 - - 19 3 - TTING & - - 194 25 - - 73 11 - ING EXPENSE - - 35 10 - - 73 11 - S - - - - - - - 73 11 - S - - - - - - - 73 11 - S - - - - - - 5 -	et sales		100	369	100 100		8 100	T	8 100		100		*
- - 129 35 - - - 19 3 SE - - 94 25 - - 73 11 - SE - - 35 10 - - 73 11 - * 35 10 - - 1 (8) - - * 2:33 * 2:12 - 1:97 - 1:93 - +2 8	JGS	1	1	240	65	l I	1		1	518	56		
- - - - - - - - - - - - - - 73 11 - - - - 35 10 - - 73 11 - 2.33 - - 35 10 - - (54) (8) - 2.33 - 2.12 - 1.93 - 1.96 - +2 8	OSS PROFIT	1	1	129	35	1	1	1	I.	19	e		1
- - 35 10 - - (54) (8) - - 2.33 - 2.12 - 1.97 - 1.93 - +2 8	RKETING & LLING EXPENSE	1	1	64	25	1		1	1	23	T		1
- 2.33 ·- 2.12 - 1.97 - 1.93 - 1.96 - +2 %	APE	1	1	35	0	1	1			(54)	(8)		
	CHANGE RATE	2.33		2.12	1	1.97	1	1.93	1	1.96	1		

*Gross return (profit) after promotional expenses

Page no.53

MAJOR 6. JUP: DIAGNOSTICS

INTI DTANT

Outter



1

TOTAL SALES & GRAPE 1980 - 1982

	É.	
	t i	
	ŗ	
1	4	
	۰.	

ģ

											1~	
	Aci	Actual 1980	Bud 19	Budget 1981	6 Months 1981	ths 1	Est. Actual 1981	ual	Prop	Proposed 1982	8-/+	
											T/2027	-1
ET SALES	n	100	ę	100	N	8 100	4	100		8		80 0
												201
)GS	5	67	21	64	-	50	n	75		1		
OSS PROFIT	-	т Ю	12	ge	4	50	J	25		ſ		1
RKETTAC .												
LLING EXPENSE	I	1	4	12	ſ	1	1	1		1		i.
APE	H	T	œ	24	Ä	20		25				1.
						+						
CHANGE RATE	2.33	4	2.12	1	1.97	1	1.93	1	1.96	1	+2 %	
		1										

*Gross return (profit) after promotional expenses

Page no.54

į

	n de fortes Specification Station	7							d de facto de serio. Esta de la constante de la Constante de la constante de la	l de la la calencia de la calencia La calencia de la cal La calencia de la cal
		(\$SU 000)	+/-% 1982/1981	100	1					Page no.55
				WN	WN	WN.	. WN	ΨQ	96 +	
			Proposed 1982	100	75	25	5	ω	1	
				89	67	22	15	7	1.56	
A		TOTAL SALES & GRAPE 1980 - 1982	Est. Actual 1981	100	67	33	1	33	1	<pre>c) after promotional expenses</pre>
2	9.7 PRODUCT SUB-GROUP SAFTIWING/OTHER *			ە	4		1	2	1.93	
SABLE			6 Months 1981	100	75	25	11	25	-1	
1				4	З	-	1	-	1.97	
MAJOR (MP :			Budget 1981	8 100	1	1	1	1	•	
				ı	I	1	1	1	2.12	
			Actual 1980	8 100	1	1	1	1	1	
				1	1	1	ł	1	2.33	(profit)
				IET SALES	SC	ROSS PROFIT	AFKETING & Siling Expense	Bana	XCHANGE RATE	*Gross return

BAYP0000019_073_0056

10. SUMMARY.

ŧ

In our plan we have detailed a number of assumptions. In summary, the most important are :-

- That the Travenol I.P.P. "Wedge pack" is not introduced to any great extent. It's wholesale introduction could be disasterous for Cutter Blood Bag sales and would also impact adversely on Koate sales.
- 2. We are able to increase our Tuta Blood Bag inventory to support our planned major business gains.
- 3. We are able to obtain a consistent supply of Koate in the potencies required in our market.
- That no further supplies of pirate Koate are dumped in our market.
- 5. That we obtain licences for 5 % and 25 % by December 1981.
- 6. That out planned increase in manpower is approved.